Add to watchlist

Silence Therapeutics plc (SLN)

Last Price$4.3(4.0%)

Market Cap$211.4B

LTM NOPAT

N/A

NOPAT margin

(320.5%)

5Y avg: (1,138.7%)

EPV as % of EV

N/A

Market-Implied Value of Growth, MIVoG as % of EV

N/A

Discount rate

N/A

Stock quality

6/10

Good

SLN

is 99.8% overvalued

learn more -->

50+

undervalued stocks

Start beating the S&P 500

#SLN Earnings Power Value Model

#Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%

S&P Outperformance 19.1%

Next 3M Predicted Return 20.3%

Discover stocks to buy now

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%

S&P Outperformance -5.5%

Next 3M Predicted Return 10.2%

See top picks now

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%

S&P Outperformance 15.4%

Next 3M Predicted Return 16.9%

See full stock list

#SLN NOPAT

#SLN Earnings Power Value and Enterprise Value

#SLN vs Peer Set: Earnings Power Value comparison

General

Earnings power value

Financial metrics

Company name

EPV as % of EV

MIVoG as % of EV

Revenue growth

EPS growth

Net income margin

Silence Therapeutics plcSLN

N/A

N/A

45.7%

(6.7%)

(170.5%)

Median Peer Set

(2.6%)

102.6%

23.0%

(56.5%)

0.8%

United Therapeutics CorporationUTHR

107.6%

(7.6%)

23.6%

25.7%

41.5%

Regeneron Pharmaceuticals, Inc.REGN

71.7%

28.3%

8.3%

10.4%

31.1%

Novo Nordisk A/SNVO

49.0%

51.0%

24.9%

142.8%

34.8%

Vertex Pharmaceuticals IncorporatedVRTX

7.1%

92.9%

11.7%

N/A

(4.9%)

Incyte CorporationINCY

0.7%

99.3%

14.8%

(94.0%)

0.8%

Alnylam Pharmaceuticals, Inc.ALNY

(6.0%)

106.0%

23.0%

(38.6%)

(12.4%)

argenx SEARGX

(12.2%)

112.2%

198.6%

(60.5%)

(24.1%)

Summit Therapeutics Inc.SMMT

(21.9%)

121.9%

N/A

(68.7%)

N/A

BeiGene, Ltd.BGNE

(66.1%)

166.1%

73.7%

(56.5%)

(35.9%)

BioNTech SEBNTX

(238.6%)

338.6%

(77.4%)

(89.7%)

24.4%

#Explore more intrinsic value tools hub for SLN